Christopher Sweeney
Dana-Farber Cancer Institute and Harvard Medical School · Dana Farber Cancer Institute and ANZUP · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christopher Sweeney as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:38 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04136353 · Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateUniversity of Sydney · active not recruiting · Prostate Cancer · study chair
- Ph3NCT02446405 · Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerUniversity of Sydney · active not recruiting · Prostatic Neoplasms · study chair
- Ph1NCT02207504 · Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate CancerDana-Farber Cancer Institute · completed · Castration-resistant Prostate Cancer · principal investigator
- Ph1NCT01574937 · XL-184+Abiraterone in Post-Chemo CRPCDana-Farber Cancer Institute · completed · Prostate Cancer · principal investigator
- Ph3NCT00309985 · Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate CancerECOG-ACRIN Cancer Research Group · completed · Metastatic Hormone-sensitive Prostate Cancer · study chair
- Ph2NCT00234494 · Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell CancerChristopher Sweeney, MBBS · completed · Bladder Cancer · study chair
- Ph2NCT00216099 · Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate CancerChristopher Sweeney, MBBS · completed · Prostate Cancer · study chair
- Ph3NCT00216060 · Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal TherapyChristopher Sweeney, MBBS · terminated · Metastatic Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate CancerR01CA208254 · NCI · DANA-FARBER CANCER INST · fiscal years 2016 to 2018 · $519,293 awarded in 2018Same name and institution; not confirmed by an ID
- Pilot Project 1: The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cell TumorsU54CA156732 · NCI · DANA-FARBER CANCER INST · fiscal years 2016 to 2017 · $78,063 awarded in 2017Same name and institution; not confirmed by an ID
- Evaluating a parthenolide analogue as a new bladder and kidney cancer therapyR03CA156048 · NCI · DANA-FARBER CANCER INST · fiscal years 2011 to 2012 · $83,156 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Statistics and Data Management CenterU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · fiscal years 2014 to 2026Named on NCT00309985
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:38 UTC. The ranking covers the 200 most relevant of 126 PubMed records, and a shared surname and initials can bring in a namesake. All 126 on PubMed
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.N Engl J Med · 20152,395 citationsRCR 78.3
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med · 20191,331 citationsRCR 51.5
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.J Clin Oncol · 2018877 citationsRCR 32.8
- Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol · 2019457 citationsRCR 15.6
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.J Clin Oncol · 2018426 citationsRCR 13.3
- Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.J Clin Oncol · 2013353 citationsRCR 9.6
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol · 2021353 citationsRCR 19.3
- 308 citationsRCR 15.8
- 228 citationsRCR 6.5
- 228 citationsRCR 13.9